Resources
Chronic Wounds Consumable Scheme Product List
The Chronic Wounds Consumable Scheme will help eligible patients manage their chronic wounds by covering the full cost of products a patient needs to heal, such as bandages, dressings and adhesives.
Australian Thalidomide Survivors Support Program – EAF and HCAF guidelines
These guidelines contain the requirements to access support from the Extraordinary Assistance Fund (EAF) and Health Care Assistance Fund (HCAF) under the Australian Thalidomide Survivors Support Program.
The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) – PDF version
Type 2 diabetes is a common chronic disease. Many Australians are at risk of developing type 2 diabetes, especially if they have certain risk factors. This tool uses a brief list of questions to assess the risk of a person developing type 2 diabetes in the next 5 years.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 6 March 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 20th meeting on 6 March 2025.
Avalglucosidase alfa Terms of Reference and Protocol Questions
This report outlines the Avalglucosidase alfa 24 Month Review Terms of Reference and Protocol Questions
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 13 December 2024
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 13 December 2024.
Australian Government response to the Inquiry into childhood rheumatic diseases – Interim Report
This is the government response to the interim report on Inquiry into childhood rheumatic diseases.
Newborn bloodspot screening variant fact sheet
The list of variants for sickle cell disease, beta thalassemia and other hemoglobinopathies are captured in this resource.
Life Saving Drugs Program – Pompe disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.
Life Saving Drugs Program – Late-Infantile Onset Batten disease (CLN2 disease) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Pompe disease – Patient test results spreadsheets
Treating physicians use the relevant spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) for the first time, or after a break.
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.
Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D).
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.
Life Saving Drugs Program – Spreadsheet for infantile-onset lysosomal acid-lipase deficiency disease (LAL-D)
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Guidelines
These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for infantile onset lysosomal acid lipase deficiency (LAL-D) under the Life Saving Drugs Program.
Date last updated: